PsyRX CNS Bio-Tech Ltd (PSRX.TA)
ValueMarkers Composite Index
DCF data not available
PsyRX CNS Bio-Tech Ltd (PSRX.TA) — VMCI valuation read
PsyRX CNS Bio-Tech Ltd (PSRX.TA) carries a VMCI composite of 40/100, 10 points below the Healthcare sector median of 50. Among mid-cap names, that gap places PSRX.TA in the bottom third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).
The PSRX.TA insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.
**Investor frame.** Value reads PSRX.TA trades at 26.0x earnings, 44% above the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 14.0% sits 4.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of 1.0x leaves covenant headroom, the line to track on PsyRX CNS Bio-Tech Ltd's next 10-Q.
PSRX.TA rose 0.4% over the trailing 7 days, with a -6.1% read on a 30-day basis.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.